Europe continuous glucose monitoring market to grow at 4% CAGR through 2035, forecasts GlobalData

As diabetes continues to affect millions across Europe, the region’s healthcare sector is rapidly shifting towards solutions that improve disease management and patient outcomes. Among the most promising advancements is the growing adoption of continuous glucose monitoring (CGM) devices, a segment set to redefine real-time diabetes care and projected to grow at a compound annual growth rate (CAGR) of approximately 4% between 2025 and 2035, forecasts GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Insulin Pumps and Continuous Glucose Monitors Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036,” reveals that Europe accounted for a sizable 20% share of the global continuous glucose monitoring market in 2025.

Senseonics has recently rolled out Eversense 365 continuous glucose monitoring (CGM) system in Europe, starting with Sweden. Germany, Spain, and Italy are expected to follow in the weeks ahead. The implantable CGM is engineered to deliver up to one year of uninterrupted glucose monitoring from a single sensor, marking a clear shift from the conventional short-duration wearables. This advancement is expected to enhance patient adherence, reduce device burden, and enable more consistent long-term glucose tracking.

Shagufta Hasan, Medical Devices Analyst at GlobalData, comments: “Europe’s CGM market is witnessing a measured but meaningful shift, with growing preference for solutions that combine clinical reliability with patient-centric design. While established markets continue to drive adoption, broader expansion will depend on improving affordability and more consistent reimbursement criteria across the region.”

Despite this progress, certain structural constraints remain. Variability in reimbursement policies, uneven healthcare infrastructure, and cost sensitivities in less mature European markets continue to limit broader penetration. At the same time, the clinical merits of CGM—such as enhanced glycemic control, reduced complications, and improved quality of life—are becoming increasingly difficult to overlook, gradually strengthening the case for broader integration into standard diabetes care pathways.

Hasan concludes: “The ongoing innovation in CGM technologies, particularly long-duration and implantable systems, could reshape diabetes management across Europe. However, unlocking the market’s full potential will depend on improving accessibility, driving physician adoption, and sustained clinical validation to ensure these advancements translate into tangible patient benefits.”